Company / Accounts Receivable
Supernus Pharmaceuticals, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$187.8M
FY2025
5-year range
$142.1M / $187.8M
FY2021-FY2025
Trend
+32.2%
vs FY2024
Sector context
#34 of 113
Health Care
What the data says
At $188M, Supernus Pharmaceuticals, Inc.'s accounts receivable ranks #34 of 113 in the Health Care sector. Accounts Receivable returned to growth in FY2025 after 2 years of decline, reaching $188M.
Based on SEC 10-K filings.
$188M in FY2025 with a 5-year CAGR of +5.9%.
Improved from $144M to $188M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +4.3%
- 5-Year CAGR
- +5.9%
- 10-Year CAGR
- -
Sector benchmark
#34 of 113 in Health CareTop 30% of 113This company $187.8M Sector average $1.1B
▼
-83.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.9%, indicating consistent growth.
- In FY2025, accounts receivable increased 32.2% year-over-year.
- Ranks #34 out of 113 companies in the Health Care sector.
- Lowest accounts receivable in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $187.8M | +32.2% |
| FY2024 | $142.1M | -1.4% |
| FY2023 | $144.2M | -12.9% |
| FY2022 | $165.5M | +11.1% |
| FY2021 | $148.9M | +5.7% |
| FY2020 | $140.9M | +61.3% |
| FY2019 | $87.3M | +29.9% |
| FY2018 | $67.2M | +2.5% |
| FY2017 | $65.6M | +57.9% |
| FY2016 | $41.5M | +60.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026